At the same time, there are many studies focused on the relationship between mutation and immunotherapy, such as the epidermal growth factor receptor (EGFR) mutations, which are the second most common oncogenic driver event in NSCLC 27. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.